Medical technology company iRhythm Technologies (NASDAQ: IRTC) will be reporting earnings this Thursday after market close. Here’s what to look for.
iRhythm beat analysts’ revenue expectations by 4.6% last quarter, reporting revenues of $192.9 million, up 30.7% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ revenue estimates.
Is iRhythm a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting iRhythm’s revenue to grow 22.9% year on year to $202 million, slowing from the 24% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.06 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. iRhythm has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 3.1% on average.
Looking at iRhythm’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. ResMed delivered year-on-year revenue growth of 11%, beating analysts’ expectations by 1.6%, and DexCom reported revenues up 13.1%, topping estimates by 0.8%. ResMed’s stock price was unchanged after the resultswhile DexCom was up 7.6%.
Read our full analysis of ResMed’s results here and DexCom’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. iRhythm is down 10.8% during the same time and is heading into earnings with an average analyst price target of $221.27 (compared to the current share price of $148.33).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
